Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?

被引:25
作者
Allegretti, Jessica R. [1 ]
Kao, Dina [2 ]
Phelps, Emmalee [3 ]
Roach, Brandi [2 ]
Smith, Justin [2 ]
Ganapini, Vincent C. [3 ]
Kassam, Zain [6 ]
Xu, Huiping [4 ,5 ]
Fischer, Monika [3 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA
[2] Univ Alberta, Zeidler Ledcor Ctr, Div Gastroenterol, Edmonton, AB, Canada
[3] Indiana Univ, Div Gastroenterol & Hepatol, Indianapolis, IN 46204 USA
[4] Indiana Univ, Dept Biostat, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA
[5] Indiana Univ, Sch Med, Indianapolis, IN USA
[6] Finch Therapeut Grp, Somerville, NJ USA
关键词
Fecal microbiota transplantation; Clostridium difficile infection; Systemic antibiotic; C; difficile recurrence prevention; FMT; SOCIETY; ADULTS; UPDATE;
D O I
10.1007/s10620-018-5450-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
IntroductionThe risk of a new Clostridium difficile infection (CDI) after FMT is unknown if non-CDI antibiotics are required. It is uncertain if anti-CDI prophylaxis or probiotics would reduce risk. We therefore aimed to compare the risk of CDI with and without antibiotic exposure and the benefit of concomitant anti-CDI antibiotic or probiotic prophylaxis.MethodsThis is a multicenter retrospective study carried out at three large FMT referral centers of patients who underwent FMT for recurrent CDI. Patients were assessed for antibiotic use, as well as concomitant use of prophylactic anti-CDI antibiotics or probiotics. Time to CDI recurrence after FMT was evaluated using the Kaplan-Meier method.ResultsA total of 404 patients were included: 63% were females, with a mean age of 61.318.8years. Mean length of post-FMT follow-up was 18.1 +/- 11.9months (range 2.2-45.2). Among the entire cohort 8.1% (n=33) experienced a CDI recurrence. Overall, 111 patients (27.4%) used a non-CDI antibiotic, of which 16.2% (n=18) experienced a CDI recurrence. Patients who used non-CDI antibiotics were more likely to develop CDI (HR 8.44, 95% CI 4.21-16.93, p<0.001). The risk of CDI recurrence was not different between patients who received anti-CDI antibiotic prophylaxis to those who did not (HR=1.88, 95% CI 0.72-4.86, p=0.2); however, probiotic prophylaxis was associated with a greater risk of CDI recurrence (HR=2.65, 95% CI 1.02-6.86, p=0.045).Conclusion Non-CDI antibiotic use was not uncommon after successful FMT and significantly increased the risk of a new episode of CDI. In this study, we found that the prophylactic use of anti-CDI antibiotics or probiotics was not protective.
引用
收藏
页码:1668 / 1671
页数:4
相关论文
共 9 条
[1]   Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure [J].
Allegretti, Jessica R. ;
Kao, Dina ;
Sitko, Jessica ;
Fischer, Monika ;
Kassam, Zain .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (01) :134-135
[2]  
Brown CC, 2018, ANN PHARMACOTHER
[3]   European consensus conference on faecal microbiota transplantation in clinical practice [J].
Cammarota, Giovanni ;
Ianiro, Gianluca ;
Tilg, Herbert ;
Rajilic-Stojanovic, Mirjana ;
Kump, Patrizia ;
Satokari, Reetta ;
Sokol, Harry ;
Arkkila, Perttu ;
Pintus, Cristina ;
Hart, Ailsa ;
Segal, Jonathan ;
Aloi, Marina ;
Masucci, Luca ;
Molinaro, Antonio ;
Scaldaferri, Franco ;
Gasbarrini, Giovanni ;
Lopez-Sanroman, Antonio ;
Link, Alexander ;
De Groot, Pieter ;
de Vos, Willem M. ;
Hoegenauer, Christoph ;
Malfertheiner, Peter ;
Mattila, Eero ;
Milosavljevic, Tomica ;
Nieuwdorp, Max ;
Sanguinetti, Maurizio ;
Simren, Magnus ;
Gasbarrini, Antonio .
GUT, 2017, 66 (04) :569-580
[4]   Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections [J].
Carignan, Alex ;
Poulin, Sebastien ;
Martin, Philippe ;
labbe, Annie-Claude ;
Valiquette, Louis ;
Al-Bachari, Hamed ;
Montpetit, Louis-Philippe ;
Pepin, Jacques .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (12) :1834-1840
[5]   European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection [J].
Crobach, M. J. T. ;
Planche, T. ;
Eckert, C. ;
Barbut, F. ;
Terveer, E. M. ;
Dekkers, O. M. ;
Wilcox, M. H. ;
Kuijper, E. J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 :S63-S81
[6]   Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and Meta-Analysis [J].
Kassam, Zain ;
Lee, Christine H. ;
Yuan, Yuhong ;
Hunt, Richard H. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (04) :500-508
[7]  
McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]
[8]   Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis [J].
Shen, Nicole T. ;
Maw, Anna ;
Tmanova, Lyubov L. ;
Pino, Alejandro ;
Ancy, Kayley ;
Crawford, Carl V. ;
Simon, Matthew S. ;
Evans, Arthur T. .
GASTROENTEROLOGY, 2017, 152 (08) :1889-+
[9]   Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection [J].
Wilcox, M. H. ;
Gerding, D. N. ;
Poxton, I. R. ;
Kelly, C. ;
Nathan, R. ;
Birch, T. ;
Cornely, O. A. ;
Rahav, G. ;
Bouza, E. ;
Lee, C. ;
Jenkin, G. ;
Jensen, W. ;
Kim, Y. -S. ;
Yoshida, J. ;
Gabryelski, L. ;
Pedley, A. ;
Eves, K. ;
Tipping, R. ;
Guris, D. ;
Kartsonis, N. ;
Dorr, M. -B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :305-317